Community Practice Connections™: Clinical Decision Making Under New Paradigms for HR+/HER2-Breast Cancer
Community Practice Connections™: Clinical Decision Making Under New Paradigms for HR+/HER2-Breast Cancer is organized by Physicians' Education Resource, LLC (PER).
Release Date: January 31, 2023
Expiration Date: January 31, 2024.
Description:
Among the subtypes of breast cancer, hormone receptor–positive (HR+)/HER2-negative (HER2-) is the most common, accounting for more than two-thirds of breast cancer cases diagnosed in the United States. For many years, treatment options for this subtype were limited, and patient outcomes were less than ideal. Growing understanding of the biology of breast cancer has led to a number of new and emerging agents that have revolutionized the treatment for this disease and, in particular, for HR+/HER2- breast cancers.
This Community Practice Connection™ program provides an in-depth review of some of the key highlights from Medical Crossfire®: Clinical Decision-Making Under New Paradigms for HR+/HER2- Breast Cancer, a satellite symposium held adjunct to the San Antonio Breast Cancer Symposium in December 2022. This unique, engaging, multimedia activity is ideal for the community-based clinician; it focuses on the practical aspects managing patients with HR+/HER2- breast cancer, putting recent clinical trial data into clinical context. The program is designed for those who did not attend the live meeting and to help reinforce learnings for those who did.
Learning Objectives:
Upon successful completion of this activity, you should be better prepared to:
• Assess efficacy and safety data regarding systemic therapies for patients with HR+/HER2- breast cancer and implications for clinical decision-making
• Individualize treatment selection, monitoring, and adverse event management for patients with HR+/HER2- breast cancer based on tumor and patient • characteristics, clinical data, and expert guidelines, in order to optimize outcomes and patient quality of life
• Discuss the utility of CDK4/6 inhibition in the adjuvant setting for patients with high-risk early-stage HR+/HER2- breast cancer, in conjunction with • clinical and molecular risk assessment methods, to identify patients who may benefit from targeted combinations.
Additional details will be posted as soon as information is available.